348 related articles for article (PubMed ID: 28605286)
1. The Durability of Basal Insulin Affects Day-to-Day Glycemic Variability Assessed by Continuous Glucose Monitoring in Type 2 Diabetes Patients: A Randomized Crossover Trial.
Iuchi H; Sakamoto M; Matsutani D; Suzuki H; Horiuchi R; Utsunomiya K
Diabetes Technol Ther; 2017 Aug; 19(8):457-462. PubMed ID: 28605286
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial.
Pasquel FJ; Lansang MC; Khowaja A; Urrutia MA; Cardona S; Albury B; Galindo RJ; Fayfman M; Davis G; Migdal A; Vellanki P; Peng L; Umpierrez GE
Diabetes Care; 2020 Jun; 43(6):1242-1248. PubMed ID: 32273271
[TBL] [Abstract][Full Text] [Related]
3. Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4.
Betônico CC; Titan SMO; Lira A; Pelaes TS; Correa-Giannella MLC; Nery M; Queiroz M
Clin Ther; 2019 Oct; 41(10):2008-2020.e3. PubMed ID: 31383366
[TBL] [Abstract][Full Text] [Related]
4. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.
Suzuki J; Yamakawa T; Oba M; Nagakura J; Shigematsu E; Tamura H; Takahashi K; Okamoto Y; Sakamoto R; Shinoda M; Takano T; Kadonosono K; Terauchi Y
Endocr J; 2019 Nov; 66(11):971-982. PubMed ID: 31270291
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
[TBL] [Abstract][Full Text] [Related]
7. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
8. Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
J Diabetes Investig; 2018 Jan; 9(1):91-99. PubMed ID: 28371461
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
[TBL] [Abstract][Full Text] [Related]
10. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
Heise T; Kaplan K; Haahr HL
J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
[TBL] [Abstract][Full Text] [Related]
11. GlucoTab-guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes.
Aberer F; Lichtenegger KM; Smajic E; Donsa K; Malle O; Samonigg J; Höll B; Beck P; Pieber TR; Plank J; Mader JK
Diabetes Obes Metab; 2019 Mar; 21(3):584-591. PubMed ID: 30328252
[TBL] [Abstract][Full Text] [Related]
12. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
[TBL] [Abstract][Full Text] [Related]
13. Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study.
Zdarska DJ; Kvapil M; Rusavy Z; Krcma M; Broz J; Krivska B; Kadlecova P
Wien Klin Wochenschr; 2014 Apr; 126(7-8):228-37. PubMed ID: 24563017
[TBL] [Abstract][Full Text] [Related]
14. Glucose-lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes.
Derosa G; Franzetti I; Querci F; Romano D; D'Angelo A; Maffioli P
Diabetes Obes Metab; 2015 Jun; 17(6):554-559. PubMed ID: 25694300
[TBL] [Abstract][Full Text] [Related]
15. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Efficacy and Safety of Insulin Detemir and Insulin Glargine in Hospitalized Patients with Type 2 Diabetes: A Randomized Crossover Trial.
Zhang T; Lin M; Li W; Fan X; Du T; Zhao Y; Zhang X
Adv Ther; 2016 Feb; 33(2):178-85. PubMed ID: 26809253
[TBL] [Abstract][Full Text] [Related]
17. [New generation of insulins: glargine U300. Summary of clinical evidence].
Musso C; Capurro L; Mingote E; Forti L; Guaita MS
Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
[TBL] [Abstract][Full Text] [Related]
18. A comparison of clinical efficacy and economic value in Basalin- and Lantus-treated patients with type 2 diabetes using continuous glucose monitoring system.
Li HQ; Lu CF; Wang J; Yin GP; Sun R; Xu XH; Liu BL; Li FF; Jing T; Lee KO; Ye L; Ma JH; Su XF
J Endocrinol Invest; 2018 Feb; 41(2):179-184. PubMed ID: 28643298
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes.
Warren ML; Brod M; Håkan-Bloch J; Sparre T; Chaykin LB
Curr Med Res Opin; 2019 Sep; 35(9):1623-1629. PubMed ID: 30974973
[No Abstract] [Full Text] [Related]
20. Traveling Across Time Zones With Type 1 Diabetes: A Pilot Study Comparing Insulin Degludec With Insulin Glargine U100.
Bevier WC; Castorino KN; Axelrod C; Haroush G; Farfan CC; Shelton N; Nelson K; Spink LA; Liu H; Kerr D
Diabetes Care; 2022 Jan; 45(1):67-73. PubMed ID: 34716211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
